Wave's pivotal trial, Dr. William Abraham is working on another heart failure trial as the new CMO at Cardiac Dimensions.
AI using single-lead smartwatch ECG flagged structural heart conditions with 86% sensitivity and 99% exclusion.
A bioadaptor implant adaptable to vessel physiology was linked to less target lesion failure and target vessel failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback